SBSarah Jane Brown

Sarah Jane Brown

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Jane Brown has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacist interventions in immigrant and refugee populations: A scoping review

    by Ann M. Philbrick, Omolayo Umaru, Sarah Jane Brown, Alec Helmke, Kathryn Momary, Jordan Peterson, Van Hellerslia


  • Open Access

    Authors' Reply to Rife et al.

    by Caitlin Bakker, Nicole Theis-Mahon, Sarah Brown

  • Open Access

    “A Supernova that Sparks in Every Direction”: A Long-Term Assessment of the Research Sprints Faculty Engagement Program

    by Jenny McBurney, Sarah Jane Brown, Mariya Gyendina, Shanda Hunt, Rebecca Orozco, Michael Peper, Greta Valentine, Benjamin Wiggins, Karna Younger

    The Research Sprints program offers faculty partners the opportunity to collaborate intensively and exclusively for one week with a team of librarians to achieve significant progress on research or teaching projects. This longitudinal study extends previous immediate and short-term assessments by interviewing Research Sprints participants at two research-intensive institutions 2–4 years after their concentrated week. The authors evaluate the enduring impact of the program on the participants’ projects, research/teaching practices, and relationships with the library. Participants report achieving project goals, improved skills and student success, and greater awareness and appreciation of librarians’ work. *The views expressed in this article, book, or presentation are those of the author and do not necessarily reflect the official policy or position of the United States Air Force Academy, the Air Force, the Department of Defense, or the U.S. Government.

  • Open Access

    The relationship between methodological quality and the use of retracted publications in evidence syntheses

    by Caitlin J. Bakker, Nicole Theis-Mahon, Sarah Jane Brown, Maurice P. Zeegers

    Background: Evidence syntheses cite retracted publications. However, citation is not necessarily endorsement, as authors may be criticizing or refuting its findings. We investigated the sentiment of these citations—whether they were critical or supportive—and associations with the methodological quality of the evidence synthesis, reason for the retraction, and time between publication and retraction. Methods: Using a sample of 286 evidence syntheses containing 324 citations to retracted publications in the field of pharmacy, we used AMSTAR-2 to assess methodological quality. We used scite.ai and a human screener to determine citation sentiment. We conducted a Pearson’s chi-square test to assess associations between citation sentiment, methodological quality, and reason for retraction, and one-way ANOVAs to investigate association between time, methodological quality, and citation sentiment. Results: Almost 70% of the evidence syntheses in our sample were of critically low quality. We found that these critically low-quality evidence syntheses were more associated with positive statements while high-quality evidence syntheses were more associated with negative citation of retracted publications. In our sample of 324 citations, 20.4% of citations to retracted publications noted that the publication had been retracted. Conclusion: The association between high-quality evidence syntheses and recognition of a publication’s retracted status may indicate that best practices are sufficient. However, the volume of critically low-quality evidence syntheses ultimately perpetuates the citation of retracted publications with no indication of their retracted status. Strengthening journal requirements around the quality of evidence syntheses may lessen the inappropriate citation of retracted publications.


  • Open Access

    Evaluating the Accuracy of scite, a Smart Citation Index

    by Caitlin Bakker, Nicole Theis-Mahon, Sarah Jane Brown

    Objectives: Citations do not always equate endorsement, therefore it is important to understand the context of a citation. Researchers may heavily rely on a paper they cite, they may refute it entirely, or they may mention it only in passing, so an accurate classification of a citation is valuable for researchers and users. While AI solutions have emerged to provide a more nuanced meaning, the accuracy of these tools has yet to be determined. This project seeks to assess the accuracy of scite in assessing the meaning of citations in a sample of publications. Methods: Using a previously established sample of systematic reviews that cited retracted publications, we conducted known item searching in scite, a tool that uses machine learning to categorize the meaning of citations. scite's interpretation of the citation's meaning was recorded, as was our assessment of the citation’s meaning. Citations were classified as mentioning, supporting or contrasting. Recall, precision, and f-measure were calculated to describe the accuracy of scite's assessment in comparison to human assessment. Results: From the original sample of 324 citations, 98 citations were classified in scite. Of these, scite found that 2 were supporting and 96 were mentioning, while we determined that 42 were supporting, 39 were mentioning, and 17 were contrasting. Supporting citations had high precision and low recall, while mentioning citations had high recall and low precision. F-measures ranged between 0.0 and 0.58, representing low classification accuracy. Conclusions: In our sample, the overall accuracy of scite's assessments was low. scite was less able to classify supporting and contrasting citations, and instead labeled them as mentioning. Although there is potential and enthusiasm for AI to make engagement with literature easier and more immediate, the results generated from AI differed significantly from the human interpretation.


  • Open Access

    Retracted publications in pharmacy systematic reviews

    by Sarah Jane Brown, Caitlin J. Bakker, Nicole R. Theis-Mahon

    Objective: Systematic reviews and other evidence syntheses, the pinnacle of the evidence pyramid, embody comprehensiveness and rigor; however, retracted data are being incorporated into these publications. This study examines the use of retracted publications in the field of pharmacy, describes characteristics of retracted publications cited by systematic reviews, and discusses factors associated with citation likelihood. Methods: Using data from Retraction Watch, we identified retracted publications in the pharmacy field. We identified all articles citing these retracted publications in Web of Science and Scopus and limited results to systematic reviews. We classified the retraction reason, determined whether the citation occurred before or after retraction, and analyzed factors associated with the likelihood of systematic reviews citing a retracted publication. Results: Of 1,396 retracted publications, 283 were cited 1,096 times in systematic reviews. Most (65.0%) (712/1096) citations occurred before retraction. Citations were most often to items retracted due to data falsification or manipulation (39.2%), followed by items retracted due to ethical misconduct including plagiarism (30.4%), or concerns about or errors in data or methods (26.2%). Compared to those not cited in systematic reviews, cited items were significantly more likely to be retracted due to data falsification and manipulation, were published in high impact factor journals, and had longer delays between publication and retraction. Conclusions: Further analysis of systematic reviews citing retracted publications is needed to determine the impact of flawed data. Librarians understand the nuances involved and can advocate for greater transparency around the retraction process and increase awareness of challenges posed by retractions.


  • Long-Term Outcomes after Early Neonatal Hyperglycemia in VLBW Infants: A Systematic Review

    by Megan E. Paulsen, Sarah Jane Brown, Katherine M. Satrom, Johannah M. Scheurer, Sara E. Ramel, Raghavendra B. Rao

    Introduction: Long-term effects of early hyperglycemia in VLBW infants are poorly characterized. The objective of this study was to systematically review the effect of early hyperglycemia on growth, metabolic health, and neurodevelopment after neonatal intensive care unit discharge in VLBW infants. Methods: The systematic review was conducted in accordance with the PRISMA guidelines. A study protocol was registered in PROSPERO (CRD42019123335). Data sources included Ovid MEDLINE, Embase, Cochrane Library, CINAHL, and Scopus. Selected studies included infants with a blood glucose concentration >150 mg/dL (8.3 mmol/L) during the first 28 days of life, a gestational age (GA) Results: Eight studies (n = 987 infants) reported long-term outcomes from 4-month corrected GA to 7 years old. Most studies compared long-term outcomes of preterm infants with and without hyperglycemia. Two studies addressed outcomes related to interventions following early hyperglycemia. Some studies found differences in growth, metabolic health, and neurodevelopment outcomes between VLBW preterm infants with hyperglycemia and without hyperglycemia, while other studies found no differences between groups. The overall graded quality of evidence was low. Conclusions: Well-designed randomized controlled and prospective studies are necessary to determine the effect of early hyperglycemia and its treatment on later metabolic and neurodevelopmental outcomes in VLBW infants. Authors propose a potential study design for standardizing the assessment of long-term metabolic and neurodevelopmental outcomes following early hyperglycemia in preterm infants.


  • Open Access

    Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma

    by Brady Anderson, Mary Vue, Nya Gayluak, Sarah Jane Brown, Lynne T. Bemis, Glenn E. Simmons

    Evidence of immunogenic cell death as a predictor of response to cancer therapy has increased interest in the high molecular group box 1 protein (HMGB1). HMGB1 is a nuclear protein associated with chromatin organization and DNA damage repair. HMGB1 is also a damage-associated molecular pattern (DAMP) protein and promotes proinflammatory signaling in a paracrine and autocrine manner. Extracellular HMGB1 can promote activation of NF-kB and is associated with several chronic inflammatory and autoimmune diseases, including sepsis, rheumatoid arthritis, atherosclerosis, chronic kidney disease, systemic lupus erythematosus (SLE), as well as cancer. In this review, we describe studies that demonstrate the use of deacetylase inhibitors and HMGB1 inhibitors to alter the expression and localization of HMGB1 in cancer cells, with a focus on lung cancer. The drugs described herein are well established and frequently used in human and small mammal studies. The main objective of this review is to summarize the potential benefit of targeting posttranslational modification of HMGB1 to decrease inflammatory signaling in the tumor microenvironment, and perhaps lead to improved response to current immunotherapeutic approaches.


  • Open Access

    Two Years in the Making: Library Resources for Transgender Topics

    by Wanda Marsolek, Katie Barrick, Sarah Jane Brown, Kristi Bergland, Caitlin Bakker, Shanda Hunt

    Inspired by Reid Boehm’s presentation “Beyond Pronouns: Caring for Transgender Medical Research Data to Benefit All People,” at the Research Data Access and Preservation Summit (RDAP) in March 2018, four librarians from the University of Minnesota (UMN) set out to create a LibGuide to support research on transgender topics as a response to Boehm’s identification of insufficient traditional mechanisms for describing, securing, and accessing data on transgender people and topics. This commentary describes the process used to craft the LibGuide, "Library Resources for Transgender Topics," including assembling a team of interested library staff, defining the scope of the project, interacting with stakeholders and community partners, establishing a workflow, and designing an ongoing process to incorporate user feedback.


  • Open Access

    Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis

    by David Flood, Jessica Hane, Matthew Dunn, Sarah Jane Brown, Bradley H. Wagenaar, Elizabeth A. Rogers, Michele Heisler, Peter Rohloff, Vineet Chopra

    Background: Effective health system interventions may help address the disproportionate burden of diabetes in low- and middle-income countries (LMICs). We assessed the impact of health system interventions to improve outcomes for adults with type 2 diabetes in LMICs.Methods and findings: We searched Ovid MEDLINE, Cochrane Library, EMBASE, African Index Medicus, LILACS, and Global Index Medicus from inception of each database through February 24, 2020. We included randomized controlled trials (RCTs) of health system interventions targeting adults with type 2 diabetes in LMICs. Eligible studies reported at least 1 of the following outcomes: glycemic change, mortality, quality of life, or cost-effectiveness. We conducted a meta-analysis for the glycemic outcome of hemoglobin A1c (HbA1c). GRADE and Cochrane Effective Practice and Organisation of Care methods were used to assess risk of bias for the glycemic outcome and to prepare a summary of findings table. Of the 12,921 references identified in searches, we included 39 studies in the narrative review of which 19 were cluster RCTs and 20 were individual RCTs. The greatest number of studies were conducted in the East Asia and Pacific region (n =20) followed by South Asia (n =7). There were 21,080 total participants enrolled across included studies and 10,060 total participants in the meta-analysis of HbA1c when accounting for the design effect of cluster RCTs. Non-glycemic outcomes of mortality, health-related quality of life, and cost-effectiveness had sparse data availability that precluded quantitative pooling. In the meta-analysis of HbA1c from 35 of the included studies, the mean difference was −0.46% (95% CI −0.60% to −0.31%,I287.8%,p <0.001) overall, −0.37% (95% CI −0.64% to −0.10%,I260.0%,n =7,p =0.020) in multicomponent clinic-based interventions, −0.87% (−1.20% to −0.53%,I291.0%,n =13,p <0.001) in pharmacist task-sharing studies, and −0.27% (−0.50% to −0.04%,I264.1%,n =7,p =0.010) in trials of diabetes education or support alone. Other types of interventions had few included studies. Eight studies were at low risk of bias for the summary assessment of glycemic control, 15 studies were at unclear risk, and 16 studies were at high risk. The certainty of evidence for glycemic control by subgroup was moderate for multicomponent clinic-based interventions but was low or very low for other intervention types. Limitations include the lack of consensus definitions for health system interventions, differences in the quality of underlying studies, and sparse data availability for non-glycemic outcomes.Conclusions: In this meta-analysis, we found that health system interventions for type 2 diabetes may be effective in improving glycemic control in LMICs, but few studies are available from rural areas or low- or lower-middle-income countries. Multicomponent clinic-based interventions had the strongest evidence for glycemic benefit among intervention types. Further research is needed to assess non-glycemic outcomes and to study implementation in rural and low-income settings.